Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC.
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Conference Correspondent published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review